Stocks and InvestingStocks and Investing
Tue, May 18, 2021
Mon, May 17, 2021
Fri, May 14, 2021
Thu, May 13, 2021
Wed, May 12, 2021

Colin Bristow Maintained (VRTX) at Strong Buy with Increased Target to $279 on, May 12th, 2021


Published on 2024-10-27 16:39:25 - WOPRAI, Colin Bristow
  Print publication without navigation


Colin Bristow of UBS, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $278 to $279 on, May 12th, 2021.

Colin has made no other calls on VRTX in the last 4 months.



There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 2 agree with Colin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $254 on, Friday, April 30th, 2021
  • Geoffrey Porges of "SVB Leerink" Maintained at Hold with Decreased Target to $250 on, Tuesday, February 2nd, 2021


These are the ratings of the 7 analyists that currently disagree with Colin


  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $260 on, Monday, May 3rd, 2021
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $262 on, Friday, April 30th, 2021
  • Gena Wang of "Barclays" Maintained at Buy and Held Target at $302 on, Wednesday, April 21st, 2021
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $252 on, Tuesday, April 20th, 2021
  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $284 on, Tuesday, February 2nd, 2021
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $347 on, Tuesday, February 2nd, 2021
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $280 on, Tuesday, February 2nd, 2021